CureVac N.V. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of EUR, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Operating activities
Profit / (Loss) before income tax
Adjustments to reconcile profit / (loss) before tax to net cash flows
Finance income
Finance expense
Depreciation and amortization
Impairment of intangible assets and property, plant and equipment
Loss on disposal of non-current assets
Impairment of assets held for sale
Impairment of inventory
Share-based payment expense
Income from release of governmental contract liabilities
Changes of provisions

Working capital changes
Decrease / (increase) in asset held for sale
Decrease / (increase) in trade receivables and contract assets
Decrease / (increase) in inventory
Decrease / (increase) in prepaid expenses and other assets
Receipts from grants from government agencies and similar bodies
Decrease in trade receivables, contract assets, asset held for sale and other assets
Decrease in trade and other payables and contract liabilities
(Decrease) / increase in other current financial and other liabilities
Decrease / (increase) in deferred taxes
Decrease in provisions
Income taxes paid
Interest received
Interest paid
Net cash flow provided by / (used in) operating activities

Investing activities
Purchase of property, plant and equipment
Purchase of intangible assets
Proceeds from asset-related grants
Purchases of financial assets
Acquisition of subsidiary, net of cash acquired
Net cash flow provided by / (used in) investing activities

Financing activities
Payments on lease obligations
Proceeds from the issuance of shares (net of transaction costs)
Proceeds from the EIB loan
Proceeds from the exercise of options
Payment on / proceeds from treasury shares/exercise of options
Proceeds from at-the-market offering program (net of transaction costs)
Proceeds from (repayment of) the EIB loan
Proceeds from the convertible loan
Payment on treasury shares
Repayments of convertible loan
Repayment of the EIB loan
Net cash flow provided by / (used in) financing activities

Net increase / (decrease) in cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period

Comments